Presentation is loading. Please wait.

Presentation is loading. Please wait.

THE EMERGING LEADERS IN PHARMACEUTICAL CARE. VISION  To become a major player in the field pharmaceuticals in the Caribbean and Latin America with a.

Similar presentations


Presentation on theme: "THE EMERGING LEADERS IN PHARMACEUTICAL CARE. VISION  To become a major player in the field pharmaceuticals in the Caribbean and Latin America with a."— Presentation transcript:

1 THE EMERGING LEADERS IN PHARMACEUTICAL CARE

2 VISION  To become a major player in the field pharmaceuticals in the Caribbean and Latin America with a work force that is committed to a level of service delivery that is unparalleled in this modern era of pharmaceutical distribution.  To use Jamaica as the major logistics hub, for regional operations for our international principals

3 MISSION  Our life- long commitment is to continue our journey to provide equal access to quality healthcare to all people of the Caribbean and Latin America.  We will attain this fundamental goal through forging relations with international partners who must be aligned with the seven core values which guide our business and it employees

4 CORE VALUES  Love for people and what we do  Vision of growth and strong profitability  Innovation to drive our success  Honesty our most treasured policy  Integrity for building good will  Service our passion which is second to none  Embracing Difference to foster the development of life-long partnerships which will enable us to seize every opportunity that exists in this global community

5 OUR PRODUCTS

6 ARISTOBET-N

7 ARISTOBET-N NEOMYCIN SULPHATE 0.5% & BETAMETHASONE SODIUM PHOSPHATE 0.1% STERILE EYE, EAR & NOSE DROPS

8 INDICATIONS EYE : Inflammatory conditions (eg.uveitis, marginal keratitis, allergic conjunctivitis, blepharitis and episcleritis) where development of bacterial infection is likely to occur. NOSE : Inflammatory conditions where infection is present or suspected. EAR : Otitis externa and other inflammatory conditions where bacterial infection is present or suspected.

9 UVEITIS IN A HUMAN EYE

10 OTITIS EXTERNA OF THE EAR

11  Eye : 1 drop instilled into the eye every one or two hours until control is achieved, when the frequency may be reduced.  Ear : 2 or 3 drops instilled into the ear, every two or three hours until control is achieved, when the frequency can be reduced.  Nose : 2 or 3 drops instilled into each nostril two or three times daily. DOSAGE AND ADMINISTRATION

12 WARNING AND PRECAUTIONS  Steroids should not be administered to "red eyes" until a definitive diagnosis has been made.  Ophthalmological treatment with steroid preparations should not be repeated or prolonged without regular review to exclude raised intra-ocular pressure or unsuspected infections.  The unnecessary topical use of neomycin products should be avoided as to minimize the occurrence of neomycin-resistant organisms (and organism cross-resistant to other aminoglycosides).

13  Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively in pregnancy. WARNING AND PRECAUTIONS Con’t

14 SIDE EFFECTS  Acute sensitization to neomycin is a rare event but can occur after topical application to the eye. Eye drops containing corticosteroids cause a serious rise in intra-ocular pressure in a small percentage of the population, including most of those with a family history of glaucoma.  Thinning of the cornea leading to perforation has occurred with use of topical corticosteroids.  Cataract is reported to have occurred after unduly prolonged treatment of eye conditions with topical corticosteroids.

15 STAFEN

16 STAFEN STAFEN STERILE EYE DROPS EACH ml CONTAINS KETOTIFEN FUMARATE BP EQUIVALENT TO KETOTIFEN 0.25 mg

17 INDICATION Stafen is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

18 ALLERGIC CONJUCTIVITIS OF A HUMAN EYE

19 DOSAGE AND ADMINISTRATION  1 drop in the affected eye (s) every 8-12 hours.

20  Stafen should not be used to treat contact lens related irritation.  Stafen should not be administered while wearing contact lenses.  Lenses may be inserted 10 minutes following administration of Stafen.WARNING AND PRECAUTIONS

21 Ocular allergic reactions:  burning or stinging  Conjunctivitis  dry eyes  eye pain and itching  keratitis  lacrimation  Mydriasis Among others. SIDE EFFECTS

22  Pregnancy: Pregnancy category C.  Lactation: It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Stafen is administered to a nursing woman. USE IN SPECIAL GROUPS

23 AVATAN

24 AVATAN STERILE EYE DROPS TRAVAPROST USP 0.04 mg.

25 Avatan Eye Drops is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or as adjunctive therapy. INDICATIONS

26 GLAUCOMA IN THE HUMAN EYE

27 DOSAGE AND ADMINISTRATION The recommended dose is one drops of Avatan in the conjunctival sac of the affected eye (s) once daily in the evening. If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic anti-glaucoma agent with Avatan, discontinue the other agent and start the following day with Avatan.

28  Travoprost should be used with caution in patients with active intraocular inflammation (iritis/uveitis).  Travoprost should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of Travoprost. WARNING AND PRECAUTIONS

29 SIDE EFFECTS The most frequently reported treatment- related side-effect is ocular hyperaemia.

30 METACARD MR

31 METACARD MR TABLET: EACH MODIFIED RELEASE TABLET CONTAINS: TRIMETAZIDINE HYDROCHLORIDE BP 35 mg

32 INDICATION Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.

33 DOSAGE AND ADMINISTRATION  One tablet to be taken at mealtimes in the morning and evening.

34 SIDE EFFECTS Trimetazidine is safe and well tolerated. Rare cases of gastrointestinal disorders, nausea & vomiting have been reported.

35 DRUG INTERACTION No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypo-lipidaemic agents or digitalis preparation.

36 OMEP-20

37 OMEP-20 CAPSULE EACH CAPSULE CONTAINS: OMEPRAZOLE BP 20 mg AS ENTERIC COATED

38 Omep capsule is indicated for short and long term treatment of duodenal ulcer, gastric ulcer, resistant ulcer, NSAIDs-induced peptic ulcer and gastroduodenal erosions, erosive reflux esophagitis, refractory reflux esophagitis, acid reflux disease, acid related dyspepsia, Zollinger-Ellison syndrome.INDICATION Omep capsule should be taken before meal.

39 Some conditions requiring the use of OMEP:  Duodenal ulcer : 20 mg once daily for 4 weeks. In severe cases 40 mg once daily for 4 weeks.  Gastric ulcer : 20 mg once daily for 8 weeks. In severe cases 40 mg once daily for 8 weeks.  Maintenance of recurrent duodenal ulcer : 20 mg once daily.  NSAIDs induced peptic ulcer and gastroduodenal erosions : 20 mg once daily for 4 weeks, followed by a further 4 weeks if not fully healed. Prophylaxis in patients with a history of NSAIDs associated gastroduodenal lesions that require continued NSAIDs treatment, 20 mg once daily. INDICATIONS cont’d

40  Impaired renal function : In such cases, dosage adjustment is not required.  Impaired hepatic function : As bioavailability and half-life is increased in patient with impaired hepatic function, the dose requires adjustment with a maximum daily dose of 20 mg.  The elderly : Dosage adjustment is not required in the elderly.WARNING AND PRECAUTIONS

41 Omep is generally well tolerated. However, Nausea, diarrhoea, flatulence, abdominal pain, constipation, dizziness and headache have been stated to be generally mild and transient and not requiring a reduction in dosage. SIDE EFFECTS

42 Omeprazole can delay the elimination of diazepam, phenytoin and warfarin. There is no evidence of an interaction with theophylline, propranolol or antacid. DRUG INTERRACTION

43 COMING SOON!! SOON!! FROM R.A WILLIAMS FROM R.A WILLIAMS

44 EYE DROPS

45 DERMATOLOGICALS


Download ppt "THE EMERGING LEADERS IN PHARMACEUTICAL CARE. VISION  To become a major player in the field pharmaceuticals in the Caribbean and Latin America with a."

Similar presentations


Ads by Google